TABLE 2.

Results of meta-analysis.

	No. studies	WMD/RR	95% confidence interval	p-value	I2	p-value
Left ventricular ejection fraction	13	4.43%	2.84%–6.02%	<0.001	91%	<0.001
PCI group	10	3.31%	2.46%–4.16%	<0.001	53%	0.02
Non-PCI group	3	7.95%	3.79%–12.12%	<0.001	96%	<0.001
Left ventricular end-diastolic diameter	9	−3.24 mm	−4.96 mm ∼ -1.52 mm	<0.001	96%	<0.001
PCI group	6	−2.28 mm	−3.73 mm ∼ -0.84 mm	0.002	91%	<0.001
Non-PCI group	3	−5.01 mm	−6.87 mm ∼ -3.15 mm	<0.001	81%	0.006
N-terminal pro-B type natriuretic peptide	11	−188.12 pg/mL	−246.75 pg/mL ∼ -129.49 pg/mL	<0.001	96%	<0.001
PCI group	10	−201.62 pg/mL	−269.92 pg/mL ∼ -133.32 pg/mL	<0.001	97%	<0.001
Non-PCI group	1	−115.34 pg/mL	−143.19 pg/mL ∼ -87.49 pg/mL	<0.001	-	-
6-min walk test	3	30.84 m	25.65m–36.03 m	<0.001	88%	<0.001
PCI group	1	25.38 m	19.09m–31.67 m	<0.001	-	-
Non-PCI group	2	41.46 m	15.84m–67.07 m	0.002	87%	0.006
Major adverse cardiovascular events	6	0.60	0.47–0.75	<0.001	0%	0.85
PCI group	6	0.60	0.47–0.75	<0.001	0%	0.85
Adverse reaction	12	0.74	0.51–1.09	0.13	54%	0.01
PCI group	9	0.89	0.60–1.32	0.57	48%	0.05
Non-PCI group	3	0.38	0.20–0.71	0.002	0%	0.40

PCI: percutaneous coronary intervention; WMD: weighted mean difference; RR: relative risk.